Möchten Sie immer auf dem neuesten Stand bleiben?

Amsterdam, 19 July 2019 Wessanen H1 and Q2 2019 interim results: Low growth and good operating result H1 and Q2 2019 highlights • Autonomous growth in own brands 0.5% for H1 (Q2: 4.4%)• Further...

This is a joint press release by PAI Partners SAS (“PAI”) and various entities (indirectly) controlled by or affiliated to Charles Jobson and/or his family members (“Charles Jobson”, and together with...

This is a joint press release by PAI Partners SAS ("PAI") and various entities (indirectly) affiliated to Charles Jobson and/or his family members ("Charles Jobson", and together with PAI, the...

This is a press release by Koninklijke Wessanen N.V. ("Wessanen" or the "Company") pursuant to the provisions of Sections 5 paragraph 4 and 6 paragraph 2 of the Dutch Decree on Public Takeover Bids...

Amsterdam, 24 April 2019 Wessanen will nominate François de Gantes as CFO and Executive Board member Wessanen is pleased to announce that François de Gantes will succeed Ronald Merckx as CFO and...

Amsterdam, 10 April 2019 Trading update Q1 2019: Strong operating result and lower revenue Q1 2019 highlights       Autonomous growth in own brands (3.2)%  Further reduction of private label...

This is a joint press release by Koninklijke Wessanen N.V. ("Wessanen" or the "Company"), PAI Partners SAS ("PAI") and various entities (indirectly) affiliated to Charles Jobson and/or his family...

Koninklijke Wessanen N.V. ("Wessanen") announces that it is in discussions with a consortium of funds managed or advised by PAI Partners SAS ("PAI") and various entities (indirectly) controlled by...

Integrated Annual Report, convocation and agenda AGM online Wessanen has published its Integrated Annual Report 2018   Our Integrated Annual Report 2018, titled "Building a new kind of food...

After having served as Wessanen's Chief Financial Officer and Executive Board member for eight years, Mr Ronald Merckx will leave Wessanen to become CFO of Centrient Pharmaceuticals. Mr Merckx's...